Talk to Us

Blue Cross and Blue Shield of Illinois policy

Natalizumab and Associated Biosimilar(s)

Natalizumab and Associated Biosimilar(s) is a public Blue Cross and Blue Shield of Illinois policy (policy RX501.059, effective May 1, 2026). It lists 2 CPT or HCPCS codes. Not a coverage decision; the payer's own document governs.

View the original policy (PDF) ↗

Payer
Blue Cross and Blue Shield of Illinois
Policy number
RX501.059
Effective
May 1, 2026
Line of business
Commercial, Medicaid
Source
medicalpolicy.hcsc.com

Codes in this policy

The CPT and HCPCS codes the policy names. A policy can name a code it excludes.

CodeOther Blue Cross and Blue Shield of Illinois policies
J2323Policies naming J2323
Q5134Policies naming Q5134

All Blue Cross and Blue Shield of Illinois policies

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.

This website uses cookies to ensure you get the best experience on our website. Learn more